Ranking Profile - Kaleido Biosciences Inc

Introduction

Kaleido Biosciences Inc (Kaleido) is a pharmaceutical company. It carries out the design and development of human microbiomes for the treatment of infectious, inflammatory, oncology, and metabolic diseases. Its proprietary product platform enables the discovery and development of novel microbiome metabolic therapies which are designed to modulate the metabolic output by function and distribution of the gut’s existing microbes. The company is investigating KB195, for treatment of urea cycle disorders; KB174, targeting hepatic encephalopathy; KB295, for treating inflammatory bowel disease; and KB109, against SARs-Cov-2 infection. It also discovers new chemistries to modulate the entire metabolic profile of the microbiome. Kaleido is headquartered in Lexington, Massachusetts, the US.